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ABSTRAK
Latar belakang: penyakit Grave atau Graves disease (GD) merupakan kondisi yang umum dijumpai pada 
tirotoksikosis. Tatalaksana GD diawali dengan pemberian obat antitiroid, meskipun pasien memerlukan waktu 
lama untuk mencapai kesembuhan atau remisi. Pada kenyataannya, lebih dari 50% pasien yang mengalami 
remisi masih berisiko mengalami kekambuhan (relaps) setelah obat dihentikan. Penelitian ini bertujuan untuk 
menilai peran faktor klinis seperti kebiasaan merokok, derajat oftalmopati, derajat pembesaran tiroid, faktor 
genetik misalnya gen CTLA-4 pada nukleotida 49 di kodon 17 pada ekson 1, gen CTLA-4 pada promotor 
318, polimorfisme gen TSHR rs2268458 pada intron 1 dan faktor imunologi sperti sel-sel T regulator (Treg) 
dan antibodi reseptor tiroid (TRAb) yang memengaruhi terjadinya relaps pada pasien dengan penyakit 
Grave di Indonesia. Metode: penelitian ini merupakan studi kasus kontrol yang membandingkan 72 subjek 
dengan relaps dan 72 subjek tanpa relaps pada 12 bulan setelah penghentian pengobatan antitiroid, yang 
memenuhi kriteria inklusi. Pemeriksaan polimorfisme genetik dilakukan menggunakan PCR-RFLP. Jumlah 
sel T regulator dihitung  menggunakan analisis sitometri alir (flow cytometry) dan pemeriksaan ELISA untuk 
mengukur TRAb. Regresi logistik dilakukan karena variabel dependen adalah variabel kategorik. Hasil: 
terdapat korelasi antara kekambuhan penyakit dan faktor keluarga (p=0,008), usia saat diagnosis ditegakkan 
(p=0,021), oftalmopati Graves derajat dua (p=0,001), pembesaran kelenjar tiroid yang melebihi batas lateral 
otot sternokleidomastoideus (p=0,040), lamanya masa remisi (p=0,029), genotipe GG dari gen CTLA-4 pada 
nukleotida 49 di kodon 17 dari ekson 1 (p=0,016), genotipe CC dari gen TSHR pada rs2268458 dari intron 1 
(p=0,003), jumlah sel T regulator (p=0,001) dan kadar TRAb (p=0,002). Kesimpulan: polimorfisme genetik 
gen CTLA-4 pada nukleotida 49 di kodon 17 pada ekson 1, gen TSHR SNP rs2268458 pada intron 1, jumlah 
sel T regulator dan kadar TRAb berperan sebagai faktor risiko terjadinya relaps pada pasien penyakit Graves.
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Kata kunci: penyakit Grave, relaps (kekambuhan), gen CTLA-4 ekson 1, gen CTLA-4 dengan promoter 
-318, gen TSHR  rs2268458 intron 1, sel-sel T regulator, Antibodi Reseptor Tiroid (TRAb).
ABSTRACT
Background: graves’ disease (GD) is the most common condition of thyrotoxicosis. The management of GD 
is initiated with the administration of antithyroid drugs; however, it requires a long time to achieve remission. In 
reality more than 50% of patients who had remission may be at risk for relapse after the drug is stopped. This 
study aimed to evaluate the role of clinical factors such as smoking habit, degree of ophtalmopathy, degree of 
thyroid enlargement; genetic factors such as CTLA-4 gene on nucleotide 49 at codon 17 of exon 1, CTLA-4 gene 
of promotor -318, TSHR gene polymorphism rs2268458 of intron 1; and immunological factors such as regulatory 
T cells (Treg) and thyroid receptor antibody (TRAb); that affecting the relapse of patients with Graves’ disease in 
Indonesia. Methods: this was a case-control study, that compared 72 subjects who had relapse and 72 subjects 
without relapse at 12 months after cessation of antithyroid treatment, who met the inclusion criteria. Genetic 
polymorphism examination was performed using PCR-RFLP. The number of regulatory T cells was counted using 
flow cytometry analysis and ELISA was used to measure TRAb. The logistic regression was used since the dependent 
variables were categorical variables. Results: the analysis of this study demonstrated that there was a correlation 
between relapse of disease and family factors (p=0.008), age at diagnosis (p=0.021), 2nd degree of Graves’ 
ophthalmopathy (p=0.001), enlarged thyroid gland, which exceeded the lateral edge of the sternocleidomastoid 
muscles (p=0.040), duration of remission period (p=0.029), GG genotype of CTLA-4 gene on the nucleotide 49 
at codon 17 of exon 1 (p=0.016), CC genotype of TSHR gene on the rs2268458 of intron 1 (p=0.003), the number 
of regulatory T cells (p=0.001) and TRAb levels (p=0.002). Conclusion: genetic polymorphisms of CTLA-4 gene 
on the nucleotide 49 at codon 17 of exon 1, TSHR gene SNP rs2268458 of intron 1, number of regulatory T cells 
and TRAb levels play a role as risk factors for relapse in patients with Graves’ disease.
Keywords: graves’ disease, relapse, CTLA-4 gene exon 1, CTLA-4 gene with promotor -318, TSHR gene 
rs2268458 intron 1, Regulatory T cells, Thyroid Receptor Antibody (TRAb).
INTRODUCTION
Graves’ disease (GD) is the most common 
condition found in thyrotoxicosis, caused by a 
complex relationship between genetic factors 
and environmental influences. The prevalence 
of GD in America and Europe is about 0.5-
1%, while in Indonesia is estimated at about 
0.05%.1-4 Genetic factors that have a role in 
this condition involve the interaction between 
Major Histocompatibility Complex (MHC) and 
non-MHC genes, i.e. imunoregulator genes and 
specific autoantigen genes. Imunoregulator genes 
that affect GD development are the cytotoxic-T 
lymphocyte-associated protein 4 (CTLA-4) gene, 
CD40 gene and protein- tyrosine phosphatase-22 
(PTPN22) gene; while the thyroid-specific 
genes are thyroglobulin and thyroid stimulating 
hormone receptor (TSHR) gene.5-8
Graves’ disease is an autoimmune disease 
of the thyroid gland caused by impaired balance 
of T helper cell 1 (Th1) and T helper 2 (Th2). 
The role of Th2 cells is more profound, but at 
the initial stage of GD, the role of Th1 cells is 
predominant.9-11 Recent studies also demonstrated 
the role of regulatory T cells (Treg), which are 
also derived from naive Th cell and controlling 
the activity of T cells through the co-stimulation 
process of dendritic cells.12-16
The management of GD is aimed to treat 
symptoms caused by hyperthyroidism. The goal 
of treatment is to control over-production of 
thyroid hormone and reducing the enlargement 
of thyroid gland. It includes antithyroid agents, 
radioactive iodine or surgical treatment such 
as thyroidectomy. Antithyroid agents are 
considered as the first-line treatment since it is 
easily implemented.17-18 The administration of 
antithyroid agents requires considerable time to 
achieve remission, which is at least 12-18 months. 
In reality, more than 50 percent of patients with 
GD who had remission may experience repeated 
symptoms of hyperthyroidism or may have 
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a relapse. Factors affecting the occurrence of 
relapse are clinical factors such as gender, age, 
smoking habit, degree of ophtalmopathy, degree 
of thyroid enlargement, duration of antithyroid 
treatment; as well as the genetic factors such as 
CTLA-4 gene, TSHR gene, thyroglobulin gene; 
and the immunological factors such as regulatory 
T cells (Treg) and thyroid receptor antibody 
(TRAb). This study aimed to evaluate the role 
of clinical, genetic and immunological factors 
affecting the relapse of patients with Graves’ 
disease in Indonesia.
METHODS
This was a case-control study, which 
compared GD patients who had relapsed 
and those without relapse at 12 months after 
cessation of antithyroid treatment. Subjects 
were recruited at outpatient clinic of Metabolism 
and Endocrinology division, Department of 
Internal Medicine, Cipto Mangunkusumo 
Hospital between August and December 2014. 
As much as 72 subjects who experienced relapse 
and 72 subjects without relapse, who met the 
inclusion criteria were obtained. Patients were 
said to relapse when after the drug was stopped 
there was an increase in T4 and/or T3 levels 
accompanied by a decrease in TSH. Definition 
of the occurrence time of relapse cannot be 
determined, but generally some researchers 
agree to use 6 months time periods after the drug 
was stopped. This study has been approved by 
Research Ethical Committee of the Faculty of 
Medicine, Universitas Indonesia (No. 540/UN2.
F1/ETHICS/2014).
Parameters evaluated in this research were 
factors affecting relapse in Graves’ disease 
including clinical factor, genetic factor and 
immunological factor. Clinical factors included 
age, gender, age at diagnosis, smoking habit, 
family history of thyroid disease, degree of 
ophtalmopathy, degree of thyroid enlargement, 
duration of antithyroid  treatment, duration 
of euthyroid period after the cessation of 
antithyroid treatment; genetic factor included 
CTLA-4 gene on nucleotide 49 at codon 17 of 
exon 1, CTLA-4 gene of promotor -318, TSHR 
gene polymorphism rs2268458 of intron 1; 
and immunological factors included regulatory 
T cells (Treg) and thyroid receptor antibody 
(TRAb).
Graves ophtalmopathy (GO) is  an 
inflammatory disorder of the orbit that occurs 
in association with autoimmune thyroid disease. 
The degree of severity can be graded using 
NOSPECS that ranges from 0 to 6. Grade 0 
means no sign or symptoms, grade 1 means 
only signs limited to upper lid retraction and 
stare with or without lid lag, grade 2 means soft 
tissue involvement (oedema of conjunctivae 
and lids, conjunctival injection, etc), grade 3 
means proptosis, grade 4 means extraocular 
muscle involvement and diplopia, grade 5 means 
corneal involvement, and grade 6 sight loss due 
to optic nerve involvement.4 This research used 
NOSPECS criteria of GO which was further 
into 3 groups: degree 0 for GO grade 0.1 and 2; 
degree 2 for GO grade 3 and 4; and degree 3 for 
GO grade 5 and 6. The degree of enlarged thyroid 
gland in our study was determined by the criteria 
used by Wang.23 The degree of enlargement can 
be graded from 1 to 3. Grade 1 if the thyroid 
gland does not reach the medial edge of the 
sternokleidomastoideus muscle, grade 2 if the 
thyroid gland reaches the sternocleidomastoideus 
muscle but not beyond the lateral edge and grade 
3 if the thyroid gland exceeds the lateral edge of 
the sternocleidomastoideus muscle.23
Examination of Genetic Polymorphisms
The examination utilized 3 ml EDTA-treated 
blood for leukocyte isolation using Ficoll-
Hypaque centrifugation. Genetic polymorphism 
examination conducted by DNA isolation using 
Promega Wizard DNA Purification Kit (Ref 
A1125) and DNA isolation procedure following 
the instructions in the kit. Concentration and DNA 
purity was calculated using nanodrop (Maestro) 
with a purity range of 1.8-2.0. Amplification of 
target DNA fragments was one using Polymerase 
Chain Reaction (PCR). Solution PCR consists of 
0.2 mg genomic DNA, 0.5 mL Taq polymerase, 
0.5μM primary forward, 0.5μM primary reverse 
and 200 mM dNTP. The DNA samples were 
amplified 35 cycles with initial denaturation at 
94°C during temperature 5 minutes, then went 
into the cycle consisted of annealing at 53°C for 
30 seconds, extension at 72°C for 30 seconds 
and over denaturation at 94°C for 30 seconds, 
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and last extension at 72°C for 7 minutes. After 
the amplification process, 5 mL of 25 mL PCR 
reaction was restricted for 3 hours at 37°C. Result 
of amplification separated by electrophoresis 
on agarose gel 2.5% for 45 minutes at 90 volts. 
Visualization of the band of DNA fragments of 
electrophoresis results was observed with a UV 
illuminator (UV long lifeTM filter Spectroline). 
Polimorfism of gene was done with Restriction 
Fragment Length Polymorphism (RFLP) method, 
and used restriction endonuclease enzyme.
Polymorphism of gene that were thought to 
influence relapse in GD and evaluated in this 
research were CTLA-4 gene on nucleotide 49 at 
codon 17 of exon 1, CTLA-4 gene of promotor 
-318 and TSHR gene rs2268458 of intron 1. 
Examination of genetic polymorphism for CTLA-
4 gene on nucleotide 49 at codon 17 of exon 
1 was done using Fnu4HI enzyme that cut the 
DNA sequences into several fragments. We used 
the 5’-GGCTTGCCTTGGATTTCAACGGC-3’ 
as forward primer and the 5’- GCTTCC 
AAAAAGTCTCACTCACC-3’ as reverse primer 
were used. Nitrogen base of Guanin (G) when 
located on position 49 will produce fragmen 98/41 
bp, but when Adenin (A) is located on position 49, 
it does not cause restriction in fragmen 129 bp.
Examination of genetic polymorphism for 
CTLA-4 gene of promotor -318 was performed 
by using an MseI restriction enzyme that cut 
DNA sequences into several fragments. The 
5’-AAATGAATTGGACTGGATGGT-3’ was 
used as forward primer and 5’-TTACGAGAAA 
GGAAGCCGTG-3’ was used reverse primer, 
which cut the DNA sequence into several 
fragments. Nitrogen base of Timin (T) when 
located on position -318 produce fragmen 132/115 
bp, but when Sitosin (C) is located on position 
-318, it does not cause restriction in fragmen 
247 bp.
Examination of genetic polymorphism for 
TSHR gene rs2268458 of intron 1 was performed 
by using restriction enzyme, AluI restriction 
endonuclease, which cut the DNA sequences 
into several fragments. The forward primers were 
5’-CCAGCAGAGGGAGCACAA-3’ and the 
reverse primers were 5’-TAGAGAATAGAGC 
AGCAAGACACT-3’. Nitrogen base of Sitosin 
(C) when located on position  intron 1 cut on 275 
bp, but when  Timin (T) is located on intron 1, 
it cut on 333 bp.
Examination of Regulatory T cells (Treg)
Examination of Treg cells was performed 
using Human Regulatory T Cell Cocktail BD 
PharMingen Kit.  The surface sections were 
stained with CD4FITC (fluoresceinsothio-
cyanate) and 10 mL CD25-PE (R-phycoerythrin); 
while the intracellular portion was stained with 
antibody anti-FoxP3-PE (R-phycoerythrin). The 
number of regulatory T cells was calculated with 
the BD FACS flowcytometer (CaliburTM®).
Thyroid Receptor Antibody (TRAb) Serum 
Levels
TRAb serum levels were measured by ELISA 
method using R & D system kits.
Statistical Analysis
Data were analyzed using SPSS version 20.0. 
In bivariate analysis, the numeric variables were 
evaluated using T-test when there was a normal 
distribution and Mann Whitney or Kruskal-
Wallis test were used when the data were not 
normally distributed. The bivariate analysis 
for categorical variables used Chi-square test, 
Fischer or Kolmogorov Smirnov test. For the 
multivariate analysis, the logistic regression was 
used since  the dependent variables were also 
categorical variables.
RESULTS
The results of the present study indicated 
that the age at diagnosis for patients with GD 
in this study was mostly less than 30 years old 
(p=0.036) and the patients who also had family 
member suffering from the disease would have 
a higher risk for relapse (p=0.008). Graves’ 
ophthalmopathy with corneal involvement or 
sight loss (the 2nd degree of ophthalmopathy), 
enlarged thyroid gland exceeding the lateral 
edge of sternocleidomastoid muscle (the 3rd 
degree), and less than 2 years remission period 
after the cessation of treatment, had greater risk 
for relapse.
Grave’s Disease patients in this study mostly 
had G allele on gene CTLA-4 nucleotide 49 
codon 17 exon 1 compared to A allele (53.5%), 
C allele on gene CTLA-4 promotor -318 (85.4%) 
than T allele, C allele on gene thyroglobulin 
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Table 1. Subjects’ characteristics
Variables Values
Gender: Female, n (%) 120/144 (83.3)
Age, Median (min-max), year 45 (27-77)
Age at diagnosis, median (min-max), 
year 32 (18-60)
Smoking habit, n (%) 4/144 (2.8)
Family factor, n (%) 24/144 (16.7)
Ophtalmopathy: degree 1 and 2, n (%) 92/144 (63.9)
Thyroid enlargement, degree 2 and 3, 
n (%) 84/144 (54.2)
Antithyroid drug: PTU, n (%) 80/144 (58.3)
Duration of antithyroid drug treatment, 
median (min-max) year 2 (1-6)
Lenth of euthyroid period, median (min-
max) year 2 (0.5-3.1)
Gene CTLA-4 nucleotide 49 exon 1: 
alel G, n (%) 154/288 (53.5)
Gene CTLA-4 promotor -318: alel C, 
n (%) 246/288 (85.4)
Gene TSHRSNP rs2268458 intron 1: 
alel T, n (%) 170/288 (59.1)
Table 2. Characteristics of immune response
Variables Median (min - max)
Number of regulator T cells 6.85 (0.89 - 24.36)
Level of TRAB (unit/L) 5.45 (0.3 - 25.95)
nucleotide 5995 codon 1980 exon 33 (52.1%) 
than T allele, and T allele on gene TSHR SNP 
rs2268458 intron 1 (59.1%) than C allele.
Data on serum level of the immune response 
in the subjects were not normally distributed, 
thus the median, minimum and maximum values 
were reported.
In this study,  it was obvious that GD subjects 
with GG genotype of  CTLA-4 gene at nucleotide 
49 codon 17 of exon 1 had a risk for relapse of 7.3 
times higher than those AA genotype; while those 
with GA genotype of CTLA-4 gene at nucleotide 
49 codon 17 of exon 1 had a risk for relapse of 
1.4 times higher than those with AA genotype. 
Graves’ Disease subjects with CC genotype TSHR 
gene SNP rs2268458 of intron 1 were at risk for 
relapse of 13.3 times higher than those with TT 
genotype.There was no difference in the risk for 
relapse between GD subjects with CC and TT 
genotypes of CTLA-4 gene of promotor -318.
The present study demonstrated that number 
of Treg cells in GD patients who had relapse 
was lower (4.43) than those who did not have 
relapse (9.25). Moreover, the TRAb serum 
level in the relapse patients (9.65 unit/L) were 
higher than those who did not have relapse (4.36 
u/L). Statistical analysis showed a significant 
correlation between the risk of relapse with the 
number of Treg cells (p 0.001) and TRAb serum 
level (p 0.002).
DISCUSSION
Most subjects in this study were female 
(83.3%). This finding is consistent with the 
the epidemiological data that the prevalence of 
Graves’ disease is mostly female with a ratio of 
5: 1 to male.1,2 The role of age on the risk for 
relapse can be evaluated from the presence of age 
differences at the time of GD diagnosis. within in 
the group who experienced relapse, the mean age 
of patients at the time of first diagnosis was 28.38 
years and in the group without relapse, was 36.12 
years (p=0.021). It indicates that the younger 
the age of GD patients, the risk of relapse was 
higher. A study conducted by Stefanie,19 which 
compared the onset of GD development between 
two groups, also found similar results.
Tobacco in cigarettes has the inflammatory 
effect that can lead to thyroid gland damage and 
immunomodulatory effects since it can suppress 
the activation of T cells, reduce the performance 
of T-killer cells and may cause defects in 
humoral and cellular immunity. Smoking can 
also decrease the effectiveness of antithyroid 
treatment and increase the growth of thyroid 
gland.20 These factors cause GD patients who 
are still actively smoking to have difficulty in 
remission and greater risk for opthalmopathy.21 
The present study demonstrated that although 
statistically there was no risk difference of 
relapse between the smoker and the non-smoker 
subject (p=0.31), all of GD patients with smoking 
habits experienced relapse. The remission 
period in smoker GD patients only last for 8-10 
months and none of the non-smoker subjects had 
experienced relapse.
Our study also provided evidences that 
GD patients who had family member with GD 
actually had risk for relapse of 2.137 times 
greater compared to those without family history 
of GD.
Fatimah Eliana                                                                                                                  Acta Med Indones-Indones J Intern Med
200
Table 4. Risk for relapse based on CTLA-4 gene at nucleotide 49 codon 17 of exon 1
CTLA-4 exon 1 Relapse No relapse P* OR (95% CI)
GG Genotype 38 (52.8) 12 (16.7) 0.016 7.312 (1.439-37.164)
GA Genotype 22 (30.5) 32 (44.4) 0.642 1.432 (0.321-6.492)
AA Genotype 12 (16.7) 28 (38.9)
* Chi-square test
Table 5. Risk for relapse based on gene CTLA-4 gene of  promotor -318
CTLA-4 promoter Relapse No relapse P* OR (95% CI)
CC Genotype 60 (83.3) 42 (58.3) 0.104 1.857 (0.782-4.408)
CT Genotype 12 (16.7) 30 (41.7)
TT Genotype 0 (0.0) 0 (0.0)
* Chi-square test
Table 3. Risk for relapse in the subjects based on clinical factors
Relapse No relapse P* OR (95% CI)
Sex, n (%)
 - Female 64 (88.9) 56 (77.8) 0.439* 0.714 (0.278-1.832)
 - Male 8 (11.1) 16 (22.2)
Age at diagnosis, n (%)
 - <30 years 40 (55.6) 14 (19.4) 0.036* 1.970 (1.136-3.416)
 - > 30 years 32 (44.4) 58 (80.6)
Smoking habit, n (%)
 - Smoking 4 (5.6) 0 (0) 0.312** 0.798 (0.238-1.053)
 - No smoking 68 (93.4) 72 (100.0)
Family factor, n (%)
 - Positive 42 (58.3) 14 (19.4) 0.008* 2.14 (1.210-3.775)
 - Negative 30 (41.7) 58 (80.6)
Degree of ophtalmopathy
 - 2nd degree 6 (8.3) 2 (2.8) 0.011*** 6.50 (0.460-11.924)
 - 1st degree 54 (75.0) 30 (41.6) 0.166*** 5.85 (1.499-9.825)
 - 0 degree 12 (16.7) 40 (55.6)
Degree of thyroid enlargement
 - 3rd degree 16 (22.2) 4 (5.6) 0.040*** 11.67 (1.112-22.381)
 - 2nd degree 38 (52.8) 26 (36.1) 0.063*** 3.370 (0.938-11.115)
 - 1st degree 18 (25.0) 42 (58.3)
Antithyroid drug
 - PTU 50 (69.4) 30 (41.7) 0.38* 1.667 (0.528-5.265)
 - Non PTU 22 (30.6) 42 (58.3)
The duration of treatment using antithyroid drug
 - < 2 years 16 (22.2) 18 (25.0) 0.731* 0.789 (0.205-3.047)
 - > 2 years 56 (77.8) 54 (75.0)
The length of euthyroid period after the cessation of antithyroid treatment
 - < 12 months 32 (44.4) 12 (16.7) 0.029* 1.862 (1.105-3.137)
 - > 12 months 40 (55.6) 60 (83.3)
* chi-square test; ** Fisher test; *** Kolmogorov Smirnov
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Ophtalmophathy is a clinical marker most 
frequently found in patients with GD.  This study, 
used the NOSPEC classification for determining 
ophtalmopathy degree. Patients with 2nd degree 
ophthalmopathy based on NOSPEC classification, 
had 6.5 times greater risk for relapse than those of 
0 degree. Graves’ disease patients with 1st degree 
ophthalmopathy, who had eyelid retraction and 
bulging eyes, had 5.85 times greater risk compared 
to those of 0 degree (p=0.011). It indicates that the 
higher the degree of ophthalmopathy, that higher 
risk for relapse is.
Enlarged thyroid gland in patients with GD 
can be determined by physical examination 
or by measuring the volume of the thyroid 
gland using ultrasound. In our study, we did 
not perform thyroid ultrasound; however we 
did perform the inspection and palpation of 
physical examination. The degree of thyroid 
enlargment can be determined by the criteria used 
in Wang’s study.23 Based on this classification, 
the GD patients with the 3rd degree had 11.7 
times greater risk for relapse compared to those 
of 1st degree (p=0.040). Patients with 2nd degree 
thyroid enlargment, had 3.37 times greater risk 
for relapse compared to those of 1st degree 
(p=0.063).
The available antithyroid drugs in Indonesia 
are PTU and methimazole. PTU is a short-acting 
drugs that should be given three times a day. Our 
study demonstrated that the types of antithyroid 
drugs, whether PTU or methimazole, did not affect 
the occurrence of relapse, with the significance 
level of p=0.383. This is also consistent with 
studies reported by Jonas24 and Wang25.
Administration of antithyroid drugs is given 
for at least 18 months; although, there are some 
who require longer treatment time.1,2 In our study, 
we limited the period of antithyroid treatment 
for as long as 2 years to determine whether 
the patients are included in the group of GD 
with difficult remission or not. The results of 
our study showed that there was no difference 
regarding the risk for relapse, between groups 
of GD patients who received treatment for 2 
years compared to those receiving treatment less 
than 2 years (p=0.731). It demonstrated that the 
length of therapy does not affect the development 
of relapse.
The definitions of remission in GD are 
various in several studies. Allahabadia26 defines 
remission as the condition in which the patient 
remains in a euthyroid state without antithyroid 
treatment for more than 6 months after the 
antithyroid treatment was ceased. Our study 
showed that patients who experienced euthyroid 
GD less than 12 months after the drug was 
stopped, had 1.86 times greater risk for relapse 
than those who continually experience euthyroid 
for more than 12 months after the drug was 
stopped. Mohlin27 reported that when GD patient 
remained in remission for more than 4 years after 
the treatment is stopped, the risk for relapse was 
getting smaller (p=0.001).
The Role of Genetic Polymorphism as the 
Risk Factor for Relapse
The CTLA-4 gene consists of 4 exons and 3 
introns. Exon is the most important part of a gene 
for carrying the message in the DNA that will 
be transcripted into mRNA and then translated 
in the ribosome to be CTLA-4 protein. Exon 1 
of CTLA-4 gene has long been known to have a 
role in various autoimmune diseases. The results 
of this study demonstrate that polymorphism of 
CTLA-4 gene of nucleotide 49 codon 17 of exon 
1 had not only a role in the risk factor for the 
development of autoimmune disease, but also 
as the risk factor for relapse.  GD subjects with 
the GG genotype had 7.31 times greater risk for 
relapse compared to those with AA genotype; 
while those with GA genotype had 1.43 times 
greater risk for relapse compared to subjects with 
AA genotype. Wang et al28 also reported that GD 
subjects with GG genotype would experience the 
relapse faster (59.6%) compared to those with 
AA genotype (7.2%) with p=0.0006. Sahin29 
study also reported that GD subjects with GG 
genotype in Turkey had 14.75 times higher risk 
for relapse than those with AA genotype.
Table 6. Risk for relapse in the subjects based on immune 
response
Relapse 
(n=72)
No relapse 
(n=72) P*
Regulatory T 
cell
4.43  
(0.89-11.3)
9.25  
(2.61-24.36) 0.001
TRAb level 
(unit/l)
9.65  
(6.30-25.95)
4.36  
(0.33-11.4) 0.002
*Mann-Whitney test
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The structure of gene is composed of a 
promotor, the structural part and the terminator. 
Promoter consists of specific DNA sequences 
located at the front of the structure of gene. 
The function of promoter is to control gene 
transcription. Polymorphisms in the promoter of 
gene may affect the CTLA-4 level by changing 
the binding of transcription factors. The results 
of our study found that GD subjects with CC 
genotype of CTLA-4 gene of promotor -318 
had 1.86 times greater risk for relapse compared 
to those with CT genotype, although it was not 
statistically significant (p=0.104). Kim30 failed 
to demonstrate the role of promotor of CTLA-4 
gene as a risk factor for relapse (p=0.109). In 
contrast, Wang28 had suggested that there was a 
role of CC genotype with a significant difference 
(p=0.0173).
In human, TSHR gene has 191 kb of DNA 
and is located on the long arm of chromosome 
14 (14q31). TSHR gene in intron 1 acts as a 
regulator for RNA, which affects the location of 
initial formation of mRNA.31 A study conducted 
by Dechairo32 has demonstrated that the TSHR 
gene rs2268458 in intron 1 had a role in GD 
events. A study report by Yin33 also suggested 
that the CC genotype of TSHR gene SNP 
rs2268458 in intron 1 had greater role in GD 
compared to its role with Hashimoto’s thyroiditis 
patients and healthy subjects. Our study found 
that the GD subjects with CC genotype for TSHR 
gene SNP rs2268458 of intron 1 had 13.3 times 
greater risk for relapse compared to those with 
TT genotype; moreover, GD subjects with CT 
genotype had 8.11 times greater risk for relapse 
compared to those with TT genotype.
The Role of the Immune Response as the Risk 
Factor for Relapse
Naive Th cells which develop into several 
subsets of T cells are Th1 cells, Th2 cells, 
regulatory T cells and Th17 cells. In GD, all of 
those subsets of T cells have a quite essential role. 
Regulatory T cells (Treg) with markers of CD4 
+ CD25 + Foxp3 are able to suppress the innate 
immune response and the acquired immune 
response; therefore, when there is a deficiency of 
Treg cells, there would be an increased activity 
of autoimmune diseases including GD.33-38
Our study demonstrated that the number of 
Treg cells in GD patients who had experienced 
relapse was lower than those who did not have 
experienced relapse. It also showed a statistically 
significant correlation between the number of 
Treg cells and the risk for relapse (p=0.001). 
Pan34 had measured regulatory T cells using 
flow cytometry and real-time quantitative RNA 
analysis in GD patients and healthy subjects and 
they found that the number of regulatory T cells 
in patients with GD (10.87) unit was lower than 
the healthy subjects (13.4) unit.
In patients with GD, thyroid stimulating 
antibody (TSAb) binds to the TSH receptor, which 
will activate adenyl cyclase and phospholipase 
A2 on the receptors. It may lead to the production 
of thyroid hormones and the growth of thyroid 
cells (thyrocytes).39,40 Our study showed a 
higher level of TRAb in GD patients who had 
experienced relapse (9.65 U/L) than those who 
did not have relapse (4.36 U/L); moreover, the 
statistical analysis also showed a significant 
correlation with p=0.002. Nedrebo41 who 
conducted a prospective study over 12 months 
periods also demonstrated that the GD patients 
who had high TRAb level (26 U/L) at the end of 
treatment period had 3.14 times greater risk for 
relapse than those with TRAb level of 15.8 U/L. 
The results of multivariate analysis with 
logistic regression showed that the clinical factors 
that affect the development of relapse in patients 
with GD is the family history, which showed 4.129 
times greater risk for relapse when the patient has 
a family member who also has suffered from GD 
and 2nd degree ophthalmopathy which showed 
6.342 times greater risk for relapse. The genetic 
factors that influenced of relapse in GD were 
GG genotype of CTLA-4 gene at nucleotide 49 
codon 17 of exon 1 with a risk of 5.963 times; 
and those with CC genotype of TSHR gene SNP 
rs 2268458 of  intron 1 with a risk of 7.931 times. 
Factors associated with immune response that 
may affect the development of relapse were the 
low number of regulatory T cells with a risk of 
1.587 times and the high TRAb level with a risk 
of 1.277 times. This research did not analyse the 
factors with most influence towards relapse in 
GD, among the clinical factors, genetic factors 
or immunological factors.
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CONCLUSION
The genetic factors that affect the development 
of relapse in GD are GG genotype of CTLA-4 
gene at nucleotide 49 codon 17 of exon 1 and 
CC genotype of TSHR gene SNP rs2268458 
of intron 1. Factors associated with immune 
response are decrease amount of T regulatory 
cells and increase level of TRAb serum. The 
clinical factors determine the recurrence are 
family history of having GD, edema or injections 
on conjunctiva or palpebral (the 2nd degree of 
ophthalmopathy according to the NOSPECS 
classification), enlarged thyroid gland exceeding 
the lateral edge of sternocleidomastoid muscle 
(the 3rd degree) and the length of euthyroid 
period of less than 6 months and the age at 
diagnosis for GD of less than 30 years. Patients 
with those characteristics should not be given 
prolong antithyroid treatment, but immediately 
given definitive therapy i.e. radioactive iodine 
or thyroidectomy.
Further research needs to be conducted to 
determine the risk of recurrence in GD models, 
using statistical methods with more number of 
sample cases and validated prospectively.
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